Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 1058-1064

  Schad, Karin ^a   Conzett, Katrin Baumann ^a   Zipser, Marie C ^a   Enderlin, Valérie ^a   Kamarashev, Jivko ^a   French, Lars E ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTIINFECTIVE AGENT; CORTICOSTEROID; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROMYCIN; FUSIDATE SODIUM; HALOMETASONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; TEMOZOLOMIDE; TRICLOSAN;

ACUTE TOXICITY; ADULT; APOPTOSIS; APPLICATION SITE BURNING; APPLICATION SITE IRRITATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CELL PROLIFERATION; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; DRY SKIN; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIDERMIS; HAIR DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; MELANOMA; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN CANCER; SKIN IRRITATION; SKIN TOXICITY; TREATMENT OUTCOME; VITILIGO; XEROSIS;

ADULT; APOPTOSIS; BENZIMIDAZOLES; DRUG ERUPTIONS; EXANTHEMA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HOMEOSTASIS; HUMANS; KERATINOCYTES; MALE; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PIGMENTATION DISORDERS; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS;

EID: 76049113589     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1766     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
2. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency inmalignantmelanoma. Cancer Res 2008;68:664-73.
3. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-51.
4. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-85.
5. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11:75-81.
6. Eggermont AM. Reaching first base in the treatment of metastatic melanoma. J Clin Oncol 2006;24:4673-4.
7. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210:39-44.
8. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
9. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1-15.
10. Dummer R, Chapman PB, Sosman JA, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 2008;26.
11. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
12. Urosevic M, Kamarashev J, Burg G, Dummer R. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood 2004;103:1796-8.
13. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
14. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-76.
15. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
16. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84.
17. Schad K, Baumann Conzett K, Enderlin V, et al. Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008, p. 26.
18. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428-35.
19. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
20. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005; 1059:16-25.
21. Kolev V, Mandinova A, Guinea-Viniegra J, et al. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 2008;10:902-11.
22. Nanney LB, Stoscheck CM, King LE, Jr., Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742-8.
23. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-12.
24. Kulms D, Schwarz T. Molecular mechanisms of UV-induced apoptosis. Photodermatol Photoimmunol Photomed 2000;16:195-201.
25. Makrantonaki E, Zouboulis CC. William J. Cunliffe Scientific Awards. Characteristics and pathomechanisms of endogenously aged skin. Dermatology 2007;214:352-60.
26. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003;307:476-80.
27. Eiling E, Brandt M, Schwarz T, Hauschild A. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. Arch Dermatol 2008;144:1236-8.
28. Mnich CD, Hoek KS, Virkki LV, et al. Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controls. Exp Dermatol 2008.